A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 Following Single Doses in Healthy Japanese Male Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs BBT 877 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Bridge Biotherapeutics
Most Recent Events
- 15 Jan 2020 Status changed from active, no longer recruiting to completed.
- 01 Nov 2019 New trial record